Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.52 |
| ▸ | CTSS | P25774 | 12/20 | 0.52 |
| ▸ | CTSL | P07711 | 10/20 | 0.52 |
| ▸ | CTSB | P07858 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169983 | 1.00 | CTSK (0.52) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL1169141 | 0.90 | CTSK (0.48) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL1169138 | 0.90 | CTSK (0.48) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL2156137 | 0.89 | CTSL (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4092781 | 0.80 | CTSK (0.66) | CTSKCTSSCTSLCTSB | |
| SCHEMBL1168977 | 0.80 | CTSK (0.65) | CTSKCTSSCTSLCTSB | |
| SCHEMBL8104303 | 0.80 | CTSK (0.65) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4092038 | 0.78 | CTSK (0.48) | CTSKCTSSCTSLCTSBRAB9A | |
| SCHEMBL4092036 | 0.78 | CTSK (0.48) | CTSKCTSSCTSLCTSBRAB9A | |
| SCHEMBL1169140 | 0.78 | CTSK (0.48) | CTSKCTSSCTSLCTSBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167507-B1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2016-03-02 | — | — | EP | disclosed |
| US-8466158-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-08-30 | — | — | US | disclosed |
| US-8198283-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2012-06-12 | — | — | US | disclosed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-7893067-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2011-02-22 | — | — | US | disclosed |
| EP-2167507-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023747-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000877-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1899336-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007006716-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | CTSK 1/4885CTSS 7/4885CTSL 2/4885 |
| US-20090023747-A1 | Cysteine Protease Inhibitors | CTSK, CTSS, CTSZ | CTSK 1/4885CTSS 2/4885CTSL 10/4885 |
| US-20090023748-A1 | Cysteine Protease Inhibitors | CTSK, CTSL, CTSV | CTSK 1/4885CTSS 7/4885CTSL 2/4885 |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | CTSK 1/4885CTSS 7/4885CTSL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.